Replies to post #4160 on Phio Pharmaceuticals Corp (PHIO)

[BioPharma]

You are right, RXi did not do public offering today, if they wait for some results out, that is a good sign.

[The Other Guy]

The timing of the MirImmune acquisition sure does raise some flags. One would think the company has some dermal scarring read outs from RX-109. But, maybe the data with sd-rxRNA in CAR T-cells was truly convincing as Geert stated.

According to the 11/29 presentation, the company still anticipates releasing preliminary Samcyprone data, preliminary RX-109 data and initiating the consumer testing in RX-231 before year end.